EEF1A1P9

Across TCGA pan-cancer cohorts, EEF1A1P9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EEF1A1P9 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher EEF1A1P9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EEF1A1P9 expression acts as an unfavorable survival marker.

OV, LUAD, and SKCM are the cancer types where EEF1A1P9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.514	0.844	.001	30	view →
LUAD	OS	Median	III,IV	0.105	0.669	<.001	30	view →
SKCM	DFS	Median	III,IV	0.135	0.654	.008	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EEF1A1P9–OV (OS)

Open the OV breakdown →